Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
53
Participants
Timeline
Start Date
September 30, 2004
Study Completion Date
December 31, 2008
Conditions
RelapseRefractory Multiple Myeloma
Interventions
DRUG
Revlimid
Trial Locations (1)
97070
Dept. of Internal Medicine II, University of Wuerzburg, Würzburg
All Listed Sponsors
lead
University of Wuerzburg
OTHER
NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter